Harrow to Acquire Tyrvaya Dry Eye Treatment from Viatris in Deal Worth Up to $100 Million

Key Facts

In a move reflecting the strategic expansion within the ophthalmic pharmaceutical sector, Harrow has entered into a definitive agreement to acquire Tyrvaya nasal spray for dry eye treatment from Viatris Inc. According to reports, the deal structure involves a $30 million upfront cash payment and up to $70 million in contingent milestone payments. This acquisition is designed to strengthen Harrow's position in the dry eye disease market by adding a treatment with a distinct mechanism of action to complement its existing Vevye franchise.

This strategic shift occurs as mid-cap pharmaceutical firms increasingly seek to bolster their core portfolios through targeted asset acquisitions. Per market analysis, the deal represents a bullish development for Harrow, providing a clear financial path to expanding its specialized offerings. The acquisition allows the company to integrate a unique therapeutic asset while managing financial risk through the milestone-based payment structure.

Looking ahead, investors will be monitoring the integration of Tyrvaya into Harrow's commercial operations, though specific price levels for the instruments remain unavailable at this time (close August 7, 2026). Market participants should also watch for broader economic catalysts, such as the upcoming Michigan Consumer Sentiment and inflation expectations data from the US, which may influence sector-wide sentiment.